Publications

Detailed Information

Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer

DC Field Value Language
dc.contributor.authorKim, Kyubo-
dc.contributor.authorChie, Eui Kyu-
dc.contributor.authorWu, Hong-Gyun-
dc.contributor.authorHa, Sung W-
dc.contributor.authorKim, Jae Sung-
dc.contributor.authorKim, In Ah-
dc.contributor.authorLee, Hyo-Pyo-
dc.date.accessioned2009-11-25T23:44:30Z-
dc.date.available2009-11-25T23:44:30Z-
dc.date.issued2005-11-07-
dc.identifier.citationGynecol Oncol. 2006 Jun;101(3):398-402. Epub 2005 Dec 5.en
dc.identifier.issn0090-8258 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16330087-
dc.identifier.urihttps://hdl.handle.net/10371/15514-
dc.description.abstractOBJECTIVE: To evaluate the efficacy and safety of concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for early stage uterine cervical carcinoma with high risk factors. METHODS: Between March 2000 and July 2002, 37 patients with stages IB-IIB uterine cervical carcinoma were treated with radical hysterectomy and bilateral pelvic lymph node dissection followed by concurrent chemoradiotherapy (POCCRT) with two courses of paclitaxel (135 mg/m(2)) and carboplatin (area under the time-concentration curve 4.5 mg min/ml) at 4-week interval. All the patients received external beam radiotherapy up to 50.4 Gy to the whole pelvis. Among these, 7 patients with close or involved resection margin received boost irradiation to the vaginal cuff (4 patients with low dose rate brachytherapy and 3 patients with external beam). Median dose of boost irradiation was 14.4 Gy (range: 14.4-34.6). RESULTS: Toxicity to POCCRT was mainly hematological and gastrointestinal, mostly grades 1 and 2. At a median follow-up of 27 months (range; 10-46), all the patients achieved local control, and 4 patients experienced distant relapses. The failure sites were as follows: bone (2 patients), paraaortic lymph node (1 patient), and supraclavicular lymph node (1 patient). CONCLUSIONS: Concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy is well tolerated and produces excellent local control rate despite of short follow-up period. This regimen could be considered for a phase III trial.en
dc.language.isoen-
dc.publisherElsevieren
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectCombined Modality Therapyen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHysterectomyen
dc.subjectLymph Node Excisionen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPaclitaxel/administration & dosage/adverse effectsen
dc.subjectPatient Complianceen
dc.subjectRadiotherapyen
dc.subjectRisk Factorsen
dc.subjectUterine Cervical Neoplasms/drug therapy/pathology/radiotherapy/*therapyen
dc.titleEfficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor김규보-
dc.contributor.AlternativeAuthor지의규-
dc.contributor.AlternativeAuthor우홍균-
dc.contributor.AlternativeAuthor김재성-
dc.contributor.AlternativeAuthor김인아-
dc.contributor.AlternativeAuthor이효표-
dc.identifier.doi10.1016/j.ygyno.2005.10.035-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share